Advertisement

Submit Manuscripts
Author Information
Subscribe/Renew
Order Reprints
Email Alerts
Feedback
RSS Feed
CME

About the Journal
Editorial Board & Staff

About JACC CME
Hardware/Software Requirements
Contact Us
Policy on Privacy and Confidentiality
Copyright Information

JACC Imaging Homepage JACC Interventions Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?
Click here
to sign up now!

ACC.org
Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions

Click here for more guidelines.
2009 Focused Updates: ACC/AHA Guidelines for STEMI and ACC/AHA/SCAI Guidelines for PCI
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
ACC 2009 Advocacy Position Statement: Principles for Comparative Effectiveness Research
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 49:1027-1034, doi:10.1016/j.jacc.2006.10.067 (Published online 25 February 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koren, M. J.
Right arrow Articles by Sweeney, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Koren, M. J.
Right arrow Articles by Sweeney, M.

Long-Term Safety of a Novel Antianginal Agent in Patients With Severe Chronic Stable Angina

The Ranolazine Open Label Experience (ROLE)

Michael J. Koren, MD, FACC*,*, Michael R. Crager, PhD{dagger} and Michael Sweeney, MD{dagger}

* Jacksonville Center for Clinical Research, Jacksonville, Florida
{dagger} CV Therapeutics, Inc., Palo Alto, California.


Figure 1
View larger version (51K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1 The ROLE Program Schematic

Disposition of subjects in preceding double-blind trials leading to the ROLE (Ranolazine Open Label Experience) program. AE = adverse event; CARISA = Assessment of Ranolazine in Stable Angina trial; MARISA = Monotherapy Assessment of Ranolazine In Stable Angina trial; pts = patients.

 

Figure 2
View larger version (7K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2 Survival Time During the ROLE Program and the Original, Randomized Trials MARISA and CARISA

Kaplan-Meier estimate. Abbreviations as in Figure 1.

 
 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement